Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to date Authorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and additional markets Announced data about our prototype's broad immune response against circulating variants when used as a booster Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of age Refining full year 2022 total revenue guidance to approximately $2.0 billion Company to host conference call today at 4:30 p.m.

Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights

Novavax will face a pivotal moment late Tuesday as NVAX stock investors watch to see whether the firm can turnaround a third-quarter profit. The post The Make-Or-Break Moment For Novavax: What To Watch In Third-Quarter Earnings appeared first on Investor's Business Daily.

The Make-Or-Break Moment For Novavax: What To Watch In Third-Quarter Earnings

Novavax Inc. NVAX, +0.15% said Tuesday a late-stage trial of its vaccine targeting the COVID variant omicron supports its continued and future use as a booster. The company said the Phase 3 trial met its main strain-change endpoint.

Novavax says Phase 3 trial of omicron-targeting COVID vaccine supports its use as a booster

Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.

Novavax says Omicron shot shows strong immune response as second booster

The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains The trial showed no benefit for a bivalent vaccine utilizing Novavax' recombinant protein/adjuvant technology GAITHERSBURG, Md. , Nov. 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company's BA.1 vaccine candidate (NVX-CoV2515) met the primary strain-change endpoint.

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

DocuSign

iQIYI

JD.com

Rapid7

Sabre

Zillow

Although an uncomfortable subject based on financial sensitivities, the topic of Nasdaq stocks to avoid cannot be avoided much longer. To be clear, it's not so much about the companies specifically.

7 Nasdaq Stocks Smart Investors Shouldn't Touch With a 10-Foot Pole

Duolingo

National Beverage

Marathon Digital Holdings

MicroStrategy Incorporated

Opendoor

Xenon Pharmaceuticals

With the Fed signaling oversized rate hikes for longer is the likely trajectory moving forward, it is understandable why investors are looking for stocks to sell rather than stocks to buy. Consumer spending continues to rise, and inflation refuses to go down.

Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.

GAITHERSBURG, Md. , Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an independent director.

Novavax Appoints Rick Rodgers to Board of Directors

GAITHERSBURG, Md. , Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational highlights on Tuesday, November 8, 2022, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth

Can this turn the stock's fortunes around?

Could This Bullish News Make Novavax a Hot Buy?

While COVID vaccinations are shrinking, it's still a multi-billion market opportunity. Novavax is sitting on a mountain of cash and its vaccine is already a blockbuster.

Buy Novavax At $20 And Hold On For The Wild Ride Up

Acumen Pharmaceuticals

Akero Therapeutics Inc

FaZe Holdings Inc

Forge Global Holdings Inc

Grove Collaborative Holdings

Immuneering Corp

Cassava Sciences Inc

Value Line

Ventyx Biosciences

Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

Investors did an about-face after the stock slumped earlier in the week.

Why Novavax Stock Rose 12.57% on Friday

Moderna

Pfizer

BioNTech SE

Stocks were set to open lower today, but the market seems to have found its groove. Everything from tech stocks to vaccine stocks are moving higher.

Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?

Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.

Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab

New Phase 3 PREVENT-19 data reinforce the Novavax COVID-19 vaccine's benefits as an adult booster in both younger and older adults, and with varying time intervals for the booster dose Phase 1/2 trial data show COVID-19-Influenza Combination vaccine candidate induced antibody and T-cell responses against SARS-CoV-2 and homologous and heterologous influenza strains GAITHERSBURG, Md. , Oct. 20, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022.

Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

FDA authorization isn't necessarily a slam dunk for a company.

Why Novavax Stock Couldn't Win on Wednesday

The shot can be administered at least six months after the completion of a primary vaccination.

FDA Authorizes Novavax Covid-19 Shot as Booster for Adults

Novavax won Food and Drug Administration for its Covid booster on Wednesday, but NVAX stock dipped slightly in response. The post Why Novavax's Uphill Battle Continues Despite Winning U.S. Booster Authorization appeared first on Investor's Business Daily.

Why Novavax's Uphill Battle Continues Despite Winning U.S. Booster Authorization

Shares of Novavax Inc. NVAX, +2.95% rallied 1.9% in morning trading Wednesday, after the biotechnology company said its protein-based COVID-19 vaccine booster was granted emergency use authorization (EUA) for adults. The booster shot is OK'd for people at least 18 years old who have completed primary vaccinations.

Novavax COVID-19 booster shot granted EUA for adults

The U.S. Food and Drug Administration on Wednesday authorized Novavax Inc's COVID-19 vaccine as a booster for adults.

U.S. FDA authorizes Novavax's COVID vaccine as booster for adults

GAITHERSBURG, Md. , Oct. 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a first booster dose at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax's Covid shots rely on protein technology used in other vaccines for decades, rather than the messenger RNA used in the Pfizer and Moderna vaccines.

FDA authorizes Novavax's Covid shots as mix-and-match booster to Pfizer or Moderna

Teladoc

Both stocks soared during the early days of the pandemic.

News for Novavax Stock (NVAX)